BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 27126635)

  • 1. Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.
    Rockenstein E; Clarke J; Viel C; Panarello N; Treleaven CM; Kim C; Spencer B; Adame A; Park H; Dodge JC; Cheng SH; Shihabuddin LS; Masliah E; Sardi SP
    Hum Mol Genet; 2016 Jul; 25(13):2645-2660. PubMed ID: 27126635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies.
    Sardi SP; Clarke J; Viel C; Chan M; Tamsett TJ; Treleaven CM; Bu J; Sweet L; Passini MA; Dodge JC; Yu WH; Sidman RL; Cheng SH; Shihabuddin LS
    Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3537-42. PubMed ID: 23297226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.
    Fishbein I; Kuo YM; Giasson BI; Nussbaum RL
    Brain; 2014 Dec; 137(Pt 12):3235-47. PubMed ID: 25351739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration.
    Soria FN; Engeln M; Martinez-Vicente M; Glangetas C; López-González MJ; Dovero S; Dehay B; Normand E; Vila M; Favereaux A; Georges F; Lo Bianco C; Bezard E; Fernagut PO
    Hum Mol Genet; 2017 Jul; 26(14):2603-2615. PubMed ID: 28520872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model.
    Kim D; Hwang H; Choi S; Kwon SH; Lee S; Park JH; Kim S; Ko HS
    Acta Neuropathol Commun; 2018 Apr; 6(1):32. PubMed ID: 29703245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models.
    Sardi SP; Singh P; Cheng SH; Shihabuddin LS; Schlossmacher MG
    Neurodegener Dis; 2012; 10(1-4):195-202. PubMed ID: 22327140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
    Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course.
    Tayebi N; Parisiadou L; Berhe B; Gonzalez AN; Serra-Vinardell J; Tamargo RJ; Maniwang E; Sorrentino Z; Fujiwara H; Grey RJ; Hassan S; Blech-Hermoni YN; Chen C; McGlinchey R; Makariou-Pikis C; Brooks M; Ginns EI; Ory DS; Giasson BI; Sidransky E
    Mol Genet Metab; 2017 Dec; 122(4):198-208. PubMed ID: 29173981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.
    Sardi SP; Cheng SH; Shihabuddin LS
    Prog Neurobiol; 2015 Feb; 125():47-62. PubMed ID: 25573151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine.
    Blandini F; Cilia R; Cerri S; Pezzoli G; Schapira AHV; Mullin S; Lanciego JL
    Mov Disord; 2019 Jan; 34(1):9-21. PubMed ID: 30589955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy.
    Sardi SP; Clarke J; Kinnecom C; Tamsett TJ; Li L; Stanek LM; Passini MA; Grabowski GA; Schlossmacher MG; Sidman RL; Cheng SH; Shihabuddin LS
    Proc Natl Acad Sci U S A; 2011 Jul; 108(29):12101-6. PubMed ID: 21730160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between glucocerebrosidase mutations and Parkinson disease.
    Migdalska-Richards A; Schapira AH
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
    Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
    Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions.
    Mahoney-Crane CL; Viswanathan M; Russell D; Curtiss RAC; Freire J; Bobba SS; Coyle SD; Kandebo M; Yao L; Wan BL; Hatcher NG; Smith SM; Marcus JN; Volpicelli-Daley LA
    J Neurosci; 2023 Jan; 43(3):501-521. PubMed ID: 36639889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.
    Rocha EM; Smith GA; Park E; Cao H; Graham AR; Brown E; McLean JR; Hayes MA; Beagan J; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Antioxid Redox Signal; 2015 Aug; 23(6):550-64. PubMed ID: 26094487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Wong YC; Krainc D
    Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease.
    Papadopoulos VE; Nikolopoulou G; Antoniadou I; Karachaliou A; Arianoglou G; Emmanouilidou E; Sardi SP; Stefanis L; Vekrellis K
    Hum Mol Genet; 2018 May; 27(10):1696-1710. PubMed ID: 29547959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models.
    Sardi SP; Viel C; Clarke J; Treleaven CM; Richards AM; Park H; Olszewski MA; Dodge JC; Marshall J; Makino E; Wang B; Sidman RL; Cheng SH; Shihabuddin LS
    Proc Natl Acad Sci U S A; 2017 Mar; 114(10):2699-2704. PubMed ID: 28223512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.